Patent 7691827 was granted and assigned to Eli Lilly and Company on April, 2010 by the United States Patent and Trademark Office.
The present invention relates to the gemcitabine prodrug 1-(2,2-difluoro-2-deoxy-β-D -ribofuranosyl)-4-(2-propyl-1-oxopentyl)aminopyrimidin-2-one useful as an oral drug for the treatment of cancer.